Mayer LD[au] - Search Results

Year	Number of Results
1949	3
1950	1
1951	3
1952	1
1955	1
1956	1
1958	1
1960	1
1967	1
1972	1
1973	1
1974	2
1981	1
1982	1
1983	1
1984	1
1985	3
1986	4
1987	1
1988	3
1989	3
1990	7
1991	1
1993	5
1994	3
1995	4
1997	5
1998	4
1999	4
2000	8
2001	10
2002	10
2003	8
2004	8
2005	4
2006	4
2007	5
2008	2
2009	3
2010	5
2011	2
2012	2
2013	1
2014	2
2015	1
2016	1
2017	2
2018	2
2019	2
2022	0

1

The liposomal formulation of doxorubicin.

Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB. Abraham SA, et al. Among authors: mayer ld. Methods Enzymol. 2005;391:71-97. doi: 10.1016/S0076-6879(05)91004-5. Methods Enzymol. 2005. PMID: 15721375

2

A comparison of liposomal formulations of doxorubicin with drug administered in free form: changing toxicity profiles.

Waterhouse DN, Tardi PG, Mayer LD, Bally MB. Waterhouse DN, et al. Among authors: mayer ld. Drug Saf. 2001;24(12):903-20. doi: 10.2165/00002018-200124120-00004. Drug Saf. 2001. PMID: 11735647 Review.

3

Improving combination cancer therapy: the CombiPlex^® development platform.

Tolcher AW, Mayer LD. Tolcher AW, et al. Among authors: mayer ld. Future Oncol. 2018 Jun;14(13):1317-1332. doi: 10.2217/fon-2017-0607. Epub 2018 Jan 24. Future Oncol. 2018. PMID: 29363994 Free article. Review.

4

Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.

Liboiron BD, Mayer LD. Liboiron BD, et al. Among authors: mayer ld. Ther Deliv. 2014 Feb;5(2):149-71. doi: 10.4155/tde.13.149. Ther Deliv. 2014. PMID: 24483194 Review.

5

Optimizing combination chemotherapy by controlling drug ratios.

Mayer LD, Janoff AS. Mayer LD, et al. Mol Interv. 2007 Aug;7(4):216-23. doi: 10.1124/mi.7.4.8. Mol Interv. 2007. PMID: 17827442 Review.

6

Tumor chemosensitization strategies based on apoptosis manipulations.

Shabbits JA, Hu Y, Mayer LD. Shabbits JA, et al. Among authors: mayer ld. Mol Cancer Ther. 2003 Aug;2(8):805-13. Mol Cancer Ther. 2003. PMID: 12939471 Review. No abstract available.

7

Molecular and pharmacological strategies to overcome multidrug resistance.

Shabbits JA, Krishna R, Mayer LD. Shabbits JA, et al. Among authors: mayer ld. Expert Rev Anticancer Ther. 2001 Dec;1(4):585-94. doi: 10.1586/14737140.1.4.585. Expert Rev Anticancer Ther. 2001. PMID: 12113091 Review.

8

Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention.

Harasym TO, Liboiron BD, Mayer LD. Harasym TO, et al. Among authors: mayer ld. Methods Mol Biol. 2010;596:291-323. doi: 10.1007/978-1-60761-416-6_13. Methods Mol Biol. 2010. PMID: 19949929 Review.

9

CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties.

Mayer LD, Tardi P, Louie AC. Mayer LD, et al. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31213803 Free PMC article. Review.

10

Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo.

Dicko A, Mayer LD, Tardi PG. Dicko A, et al. Among authors: mayer ld. Expert Opin Drug Deliv. 2010 Dec;7(12):1329-41. doi: 10.1517/17425247.2010.538678. Expert Opin Drug Deliv. 2010. PMID: 21118030 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results